PMID- 32115498
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 43
IP  - 3
DP  - 2020
TI  - Selenoprotein P; P for Plasma, Prognosis, Prophylaxis, and More.
PG  - 366-374
LID - 10.1248/bpb.b19-00837 [doi]
AB  - Selenoprotein P (SeP) is one of the 25 human selenocysteine (Sec)-containing 
      proteins, and is generally thought to function as a plasma carrier of the trace 
      element selenium in the body. Recent studies, however, indicate unsuspected 
      pivotal roles of SeP in human diseases, particularly in type 2 diabetes mellitus 
      (T2DM) and pulmonary arterial hypertension (PAH). In this review, we will 
      summarize the characteristics of SeP and recent advances in the field, especially 
      focusing on the emerging roles of SeP in pathophysiological conditions. We will 
      also discuss potential medical/pharmaceutical applications targeting SeP.
FAU - Tsutsumi, Ryouhei
AU  - Tsutsumi R
AD  - Laboratory of Metabolism and Molecular Biology, Graduate School of Pharmaceutical 
      Sciences, Tohoku University.
FAU - Saito, Yoshiro
AU  - Saito Y
AD  - Laboratory of Metabolism and Molecular Biology, Graduate School of Pharmaceutical 
      Sciences, Tohoku University.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Biomarkers)
RN  - 0 (Selenoprotein P)
RN  - H6241UJ22B (Selenium)
SB  - IM
MH  - Animals
MH  - Biomarkers
MH  - Diabetes Mellitus, Type 2/physiopathology
MH  - Humans
MH  - Plasma
MH  - Prognosis
MH  - Pulmonary Arterial Hypertension/physiopathology
MH  - Selenium/metabolism
MH  - Selenoprotein P/*blood/drug effects/*physiology
OTO - NOTNLM
OT  - pulmonary arterial hypertension
OT  - selenium
OT  - selenoprotein P
OT  - type 2 diabetes mellitus
EDAT- 2020/03/03 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/03/03 06:00
PHST- 2020/03/03 06:00 [entrez]
PHST- 2020/03/03 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1248/bpb.b19-00837 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2020;43(3):366-374. doi: 10.1248/bpb.b19-00837.